Halozyme Therapeutics (HALO) has drawn fresh investor attention after reporting Q4 2025 revenue of US$451.77 million, which surpassed expectations, even as earnings per share of US$0.24 came in below forecasts.

At a share price of US$64.49, Halozyme’s 7-day share price return of 4.64% contrasts with a 90-day decline of 9.42%. The 3-year total shareholder return of 68.25% points to longer-term momentum that recent Q4 news and guidance updates have brought back into focus.

If Halozyme’s latest move has you thinking about where else growth stories could emerge in healthcare, it may be worth screening for other promising healthcare AI names through our curated list of 36 healthcare AI stocks.

So with Halozyme trading at US$64.49 against higher analyst price targets and a solid multi year shareholder return, should you see current levels as a valuation gap to explore, or as a sign that markets are already pricing in future growth?

Most Popular Narrative: 23.7% Undervalued

With Halozyme last closing at $64.49 against a narrative fair value of $84.50, the widely followed view is that the current price leaves a sizeable gap, built on detailed assumptions about royalties, margins and capital allocation.

The company's expanding network of global partnerships and the ramp-up of recently launched subcutaneous biologics (e.g., OCREVUS ZUNOVO, Opdivo Qvantig, Tecentriq Hybreza, RYBREVANT SC) provide a robust set of new and diversified royalty streams that are still early in their adoption curve. As these launches mature and penetration increases, especially in emerging and international markets, significant sequential revenue and EBITDA growth is anticipated.

Curious what sits behind that fair value gap? The narrative leans on a specific path for revenue, earnings and margins, plus a tighter share count and a defined discount rate. The mix of these moving parts is what drives the $84.50 figure.

Result: Fair Value of $84.50 (UNDERVALUED)

However, this hinges on ENHANZE maintaining its relevance and key partnerships staying intact. Regulatory or patent setbacks could quickly challenge that 23.7% upside story.

Another Take: Multiples Point To A Richer Price

The fair value model suggests Halozyme looks 69% undervalued, yet its current P/E of 24.1x is higher than the fair ratio of 18.4x, the US Biotechs average of 16x, and the peer average of 20.2x. This raises the question of whether the stock is a bargain or whether optimism is already reflected in the share price.

Next Steps

With both bullish and cautious views in play, it helps to see the full picture quickly and decide where you stand, starting with the 3 key rewards and 4 important warning signs.

Looking for more investment ideas?

If you stop with just one company, you risk missing other opportunities that might fit your goals even better. Consider broadening the field before making your next move.

• Spot potential mispricings early by scanning our curated set of 58 high quality undervalued stocks that combine quality with appealing valuations.
• Strengthen your income stream by reviewing 13 dividend fortresses that focus on higher yielding companies with staying power.
• Prioritise resilience by checking 68 resilient stocks with low risk scores built around companies with lower risk scores and steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.